Maze Therapeutics (NASDAQ:MAZE) Rating Increased to Strong-Buy at Leerink Partnrs

Leerink Partnrs upgraded shares of Maze Therapeutics (NASDAQ:MAZE) to a strong-buy rating in a report released on Tuesday,Zacks.com reports.

MAZE has been the subject of several other research reports. Guggenheim started coverage on Maze Therapeutics in a report on Tuesday. They issued a “buy” rating and a $19.00 price target for the company. JPMorgan Chase & Co. started coverage on Maze Therapeutics in a report on Tuesday. They issued an “overweight” rating and a $30.00 price target for the company. Finally, Leerink Partners started coverage on Maze Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $28.00 price target for the company.

Maze Therapeutics Stock Performance

Maze Therapeutics stock opened at $10.57 on Tuesday. Maze Therapeutics has a 12 month low of $10.08 and a 12 month high of $17.00.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.